New cancer drug GEN1057 tested in humans – trial ends early
NCT ID NCT06573294
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This early-stage trial tested a new antibody called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
National Cancer Center, Tsukiji 5-1-1
Tokyo, Japan
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
Start Madrid Centro Integral Oncologico Clara Campal CIOCC
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.